Federal Official Gazette
No updates.
ANS news
ANS incorporates drug to treat severe Chronic Obstructive Pulmonary Disease
The technology becomes mandatory coverage in supplementary health as of Mar 2, 2026. One of the premises of the incorporation decision was a discount offered by the laboratory that produces the drug, which will apply not only to the treatment of severe Chronic Obstructive Pulmonary Disease, but will extend to all health conditions for which Dupilumab is already incorporated into the Rol. To that end, for the first time, the holder of the technology will sign a commitment agreement with ANS undertaking to guarantee the discount offered.
Decisions of the 14th Extraordinary Meeting of the Board of Directors (DICOL) of 2025
00:10:41 – START
00:11:05 – ITEM 1 DIPRO – Decision on the proposed update of the List of Health Procedures and Events (Rol) – Preliminary Recommendation Technical Note (NTRP) concerning Technical Analysis Units (UATs) 76 and 77.
DECISION: ITEM DECIDED.
00:21:24 – ITEM 2 DIPRO – Decision on the proposed update of the List of Health Procedures and Events (Rol) – Final Recommendation Technical Note (NTRF) concerning UATs 160 and 166.
DECISION: ITEM DECIDED.
00:44:09 – ITEM 3 DIPRO – Decision on the proposed update of the List of Health Procedures and Events (Rol), related to the health technologies recommended by the National Commission for the Incorporation of Technologies into the Unified Health System (Conitec).
DECISION: ITEM DECIDED.
01:03:12 – ITEM 4 DIDES – Approval of the execution of a Technical Cooperation Agreement between ANS and the Serviço Social da Indústria (Sesi).
DECISION: ITEM APPROVED.
Open public consultations
There are no open public consultations.
Scheduled public hearings
There is no public hearing scheduled.
Open public calls for input
There are no open public calls for input.
Open public calls
No updates.
Other news
Co-payment leads workers to avoid using their health plan
Source: oglobo.globo.com · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.